Regulus Therapeutics to Join Russell 3000 and 2000 Indexes

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company specializing in microRNA-targeting medications, announced on June 4, 2024, that it anticipates inclusion in both the Russell 3000® Index and the Russell 2000® Index following the annual reconstitution of the Russell US Indexes. This reconstitution, identifying the 4,000 largest U.S. stocks based on market capitalization as of April 30th, will be effective at the opening of U.S. equity markets on July 1st, 2024. The announcement follows a preliminary list of additions released on May 24th.

The annual reconstitution of the Russell US Indexes involves capturing the largest U.S. stocks and ranking them by total market capitalization. Companies included in the all-cap Russell 3000® Index are also automatically added to either the large-cap Russell 1000® Index or the small-cap Russell 2000® Index, along with relevant growth and value style indexes. FTSE Russell, which oversees the Russell indexes, determines membership based on market-capitalization rankings and style attributes.

Regulus’ Chief Executive Officer, Jay Hagan, expressed pride in the company's expected addition to these indexes, highlighting the recognition as an indicator of the company's progress and the value of its pharmaceutical pipeline, including the RGLS8429 program aimed at treating patients with ADPKD (Autosomal Dominant Polycystic Kidney Disease).

The Russell indexes are extensively used by investment managers and institutional investors to guide index funds and serve as benchmarks for active investment strategies. By the end of 2023, approximately $10.5 trillion in assets were benchmarked against the Russell US indexes. FTSE Russell, a significant global index provider, manages these indexes.

Fiona Bassett, CEO of FTSE Russell, emphasized the importance of annual rebalancing in maintaining accurate benchmarks that reflect the evolving U.S. economy. She noted that the Russell indexes, celebrating their 40th year, continuously adapt to mirror their respective market segments accurately and impartially.

Regulus Therapeutics Inc., headquartered in San Diego, CA, focuses on the discovery and development of innovative microRNA-targeting medicines. The company leverages its expertise in oligonucleotide drug discovery and development to build a diverse pipeline supported by a strong intellectual property portfolio.

FTSE Russell, a leading global provider of benchmarking, analytics, and data solutions, offers a comprehensive range of reliable indexes. These tools help investors worldwide measure and benchmark markets across various asset classes, styles, or strategies. For over three decades, FTSE Russell's indexes have been chosen by asset owners, managers, ETF providers, and investment banks for benchmarking investment performance and creating index-based products.

FTSE Russell adheres to high industry standards in index design and governance, employing transparent, rules-based methodologies. Independent committees of leading market participants inform these methodologies. The company fully embraces the IOSCO Principles, with its Statement of Compliance having received independent assurance. FTSE Russell's index innovation is client-driven, enabling continuous enhancement of its offerings.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!